Get the Stockscreener App
7.99
2.83%
0.22
Avalo Therapeutics Inc stock is traded at $7.99, with a volume of 8,115.
It is up +2.83% in the last 24 hours and up +14.31% over the past month.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
See More
Previous Close:
$7.77
Open:
$7.6
24h Volume:
8,115
Relative Volume:
0.09
Market Cap:
$83.90M
Revenue:
$1.93M
Net Income/Loss:
$-7.96M
P/E Ratio:
-0.00226
EPS:
-3530.8178
Net Cash Flow:
$-36.78M
1W Performance:
+3.77%
1M Performance:
+14.31%
6M Performance:
-14.74%
1Y Performance:
+83.68%
1-Day Range:
$7.60
$8.00
1-Week Range:
$7.06
$8.00
52-Week Range:
$4.36
$34.46
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
540 GAITHER ROAD, ROCKVILLE
Compare AVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
7.99 | 83.90M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
AVTX’s 52-Week Rollercoaster: From $4.35 to $34.46 – What’s Next for Investors? - The InvestChronicle
PSTV Rallies, TOVX Gears Up For VIRAGE Trial Data, Will AVTX's LOTUS Bloom? - RTTNews
(AVTX) Investment Analysis - Stock Traders Daily
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update - Defense World
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at Piper Sandler - Defense World
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated by Analysts at Piper Sandler - MarketBeat
Piper Sandler Initiates Coverage of Avalo Therapeutics (AVTX) with Overweight Recommendation - Nasdaq
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga India
Piper Sandler Initiates Avalo Therapeutics at Overweight With $48 Price Target -February 28, 2025 at 07:54 am EST - Marketscreener.com
Piper Sandler sets $48 target on Avalo Therapeutics stock - Investing.com
Avalo Therapeutics (NASDAQ:AVTX) Upgraded by Wedbush to "Strong-Buy" Rating - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) Now Covered by Analysts at Wedbush - MarketBeat
Avalo Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Avalo Therapeutics (NASDAQ:AVTX) Trading Up 3.1%Time to Buy? - MarketBeat
Avalo Therapeutics initiated with an Outperform at Wedbush - MSN
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at Wedbush - Defense World
Avalo Therapeutics (NASDAQ:AVTX) Upgraded at Wedbush - Defense World
Avalo climbs as Wedbush issues bullish view on lead asset - MSN
(AVTX) Trading Advice - Stock Traders Daily
Avalo stock climbs on Wedbush bullish view (AVTX:NASDAQ) - Seeking Alpha
Wedbush Initiates Avalo Therapeutics With Outperform Rating, $18 Price Target -February 21, 2025 at 07:51 am EST - Marketscreener.com
(AVTX) Technical Data - Stock Traders Daily
Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - The Manila Times
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Up 176.2% in January - MarketBeat
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Decreases By 11.8% - MarketBeat
(AVTX) Investment Report - Stock Traders Daily
When (AVTX) Moves Investors should Listen - Stock Traders Daily
AVTX (Avalo Therapeutics) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Drops By 11.8% - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) Trading Up 6.5%Still a Buy? - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) Stock Price Up 6.5% – Still a Buy? - Defense World
(AVTX) Trading Signals - Stock Traders Daily
Avalo Therapeutics appoints first chief strategy officer - Pennsylvania Business Report
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer - citybiz
Avalo Therapeutics Names Biogen Veteran Jennifer Riley as Chief Strategy Officer to Lead $10B Market Push - StockTitan
(AVTX) Proactive Strategies - Stock Traders Daily
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Increases By 340.4% - MarketBeat
BTIG Research Begins Coverage on Avalo Therapeutics (NASDAQ:AVTX) - Defense World
Avalo Therapeutics initiated with a Buy at BTIG - Yahoo Finance
BTIG optimistic on Avalo Therapeutics stock with potential for transformative Phase 2b trial results - Investing.com Canada
(AVTX) Trading Report - Stock Traders Daily
LUCID CAPITAL MARKETS Initiates Coverage of Avalo Therapeutics (AVTX) with Buy Recommendation - MSN
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Drops By 46.9% - MarketBeat
Avalo Therapeutics (AVTX) Is a Potential Hidden Gem with Significant Risk - TipRanks
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):